NCT05141747 2022-02-23A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.Shanghai Miracogen Inc.Phase 2 Unknown60 enrolled